PC
ALXN

Paulson & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Paulson & Co’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-153,000
Closed -$18.7M – 117
2016
Q4 		$18.7M Buy
+153,000
New +$18.7M 0.24% 48

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Paulson & Co's ALXN Position: Q2 2021 in Review

Paulson & Co sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 1,400,000 shares — an estimated $214M sold.

Paulson & Co first reported a position in ALXN in Q1 2016 and held it in 8 quarters. The position peaked at $214M in Q1 2021. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Paulson & Co reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Paulson & Co sold 1,400,000 Alexion Pharmaceuticals shares in Q2 2021, an estimated $214M.
  • Paulson & Co first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 8 quarters.
  • Paulson & Co's Alexion Pharmaceuticals position peaked at $214M in Q1 2021.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Paulson & Co's 13F filing for Q2 2021, filed 16 Aug 2021.